TransMedics Group (TMDX) Gets a Buy from TD Cowen

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on TransMedics Group (TMDX – Research Report), with a price target of $146.00. The company’s shares closed yesterday at $129.81.

Confident Investing Starts Here:

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
• Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

Jennings covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Medtronic, and Establishment Labs Holdings. According to TipRanks, Jennings has an average return of 4.6% and a 52.11% success rate on recommended stocks.

Currently, the analyst consensus on TransMedics Group is a Moderate Buy with an average price target of $124.00, implying a -4.48% downside from current levels. In a report released yesterday, Piper Sandler also reiterated a Buy rating on the stock with a $145.00 price target.

Based on TransMedics Group’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $143.54 million and a net profit of $25.68 million. In comparison, last year the company earned a revenue of $96.85 million and had a net profit of $12.2 million

Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TMDX in relation to earlier this year. Last month, Edward M Basile, a Director at TMDX sold 5,000.00 shares for a total of $632,250.00.